How to Help Your Patients Save Money on NovoEight: A Provider's Guide to Savings Programs

For providers managing patients with hemophilia A, the cost of factor VIII therapy is one of the most significant barriers to consistent, effective care. Annual costs for hemophilia A treatment can range from hundreds of thousands to over a million dollars for severe patients on prophylaxis, depending on body weight, factor type, and dosing frequency. Understanding the complete landscape of financial assistance programs for NovoEight (turoctocog alfa) is an essential clinical competency in 2026.

This guide walks through every available cost-reduction program, eligibility criteria, and how your practice can streamline the enrollment process.

Program 1: NovoCare Copay Savings Card

The NovoCare Copay Savings Card is the most broadly applicable savings program for commercially insured patients with hemophilia A on NovoEight.

Benefit: As low as $0 patient out-of-pocket per fill, up to a maximum of $12,000 in savings per calendar year

Eligibility: Commercial insurance coverage required; patient must have NovoEight covered on their plan. Government program beneficiaries (Medicare, Medicaid, VA, TRICARE) are excluded.

Enrollment: Call NovoCare (1-844-668-6732) or enroll online at novoeight.com. Your NovoCare RBCL can also enroll patients during your HTC or office visits.

Annual reset: The $12,000 maximum resets each January 1. Remind patients to re-activate or re-enroll at the start of each calendar year.

Program 2: NovoSecure Patient Assistance Program (PAP)

The NovoSecure PAP provides NovoEight at no cost to qualifying uninsured or underinsured patients. This is a critical program for practices serving underresourced populations.

Eligibility criteria: US citizen or legal resident; uninsured or insurance does not cover NovoEight; meets Novo Nordisk income guidelines; valid prescription for an FDA-approved indication

Application: Healthcare provider and patient must both complete sections of the PAP application. Fax to 1-866-488-6576 or contact NovoCare for electronic submission options.

Note: Patients enrolled in the PAP cannot seek reimbursement from any government program for medications provided through the PAP. Re-certification is typically required annually.

Program 3: JumpStart Program (Insurance Initiation Gap)

When a new NovoEight prescription is awaiting insurance prior authorization approval, the JumpStart Program provides a limited free supply to bridge the gap — preventing treatment interruption during the PA process. This is particularly useful for patients switching from another factor product or initiating NovoEight for the first time while insurance paperwork is processed.

Key use case: New prescription submitted; PA pending review; patient has 0-5 day supply remaining

Activation: Contact NovoCare (1-844-668-6732) and confirm patient eligibility and insurance status

Program 4: Interim Program (Ongoing Coverage Gaps)

For established NovoEight patients who experience a lapse in commercial insurance coverage — such as between jobs, during an appeal, or in a waiting period for new coverage — the Interim Program provides continued medication to prevent a dangerous therapy gap.

Key use case: Employed patient loses job and insurance; COBRA lapse; insurance appeal pending for 30+ days

Best practice: Educate all NovoEight patients proactively about this program during annual visits so they know to call NovoCare if their coverage changes

Program 5: Federal HTC Funding and State Programs

Federally funded HTCs receive support from the CDC's Division of Blood Disorders. Some HTC programs have limited supplemental factor funding for patients in acute need — ask your HTC administrator about available discretionary resources. Additionally, many state Medicaid programs have specific hemophilia carve-outs or supplemental coverage pools administered through state health departments.

Program 6: Trial Prescription Program

Novo Nordisk offers a Trial Prescription Program for patients newly initiating NovoEight who have commercial insurance. This provides initial product at reduced cost as the patient begins therapy and prior authorization is established. Contact NovoCare (1-844-668-6732) to confirm current availability and patient eligibility.

Practical Implementation: Building Access Support Into Your Practice Workflow

Best practices for HTC and hematology practices:

Screen all new NovoEight patients for copay card eligibility at the time of first prescription

Assign a patient navigator or social worker to manage NovoCare program enrollments

Build a relationship with your NovoCare RBCL — meet with them quarterly to stay current on program changes

Add an annual insurance/coverage review to every HTC visit to catch upcoming coverage gaps proactively

Document all cost-assistance program enrollments in the patient's chart for continuity of care

medfinder: Reducing Pharmacy Coordination Burden

When patients are enrolled in savings programs but still can't locate their NovoEight vial strength at a specialty pharmacy, medfinder can take the pharmacy coordination burden off your staff. Patients submit their medication details and location — medfinder calls specialty pharmacies and reports back which ones can fill the prescription. This supports both patient satisfaction and clinical adherence.

For the patient-facing version of this savings guide, see: How to Save Money on NovoEight in 2026: Coupons, Discounts, and Patient Assistance.